• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fortress Biotech Inc. (Amendment)

    2/14/23 5:01:00 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBIO alert in real time by email
    SC 13G/A 1 tm236168d23_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    FORTRESS BIOTECH, INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    34960Q109

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: 

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP NO.  34960Q109 Page 2 of 7

     

    CUSIP No.  34960Q109
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 7,968,056
    (7) Sole dispositive power 0
    (8) Shared dispositive power 7,968,056
    (9) Aggregate amount beneficially owned by each reporting person 7,968,056
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 7.3%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO.  34960Q109 Page 3 of 7

     

    CUSIP No.  34960Q109
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 7,968,056
    (7) Sole dispositive power 0
    (8) Shared dispositive power 7,968,056
    (9) Aggregate amount beneficially owned by each reporting person 7,968,056
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 7.3%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO.  34960Q109 Page 4 of 7

     

    CUSIP No.  34960Q109
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 7,968,056
    (7) Sole dispositive power 0
    (8) Shared dispositive power 7,968,056
    (9) Aggregate amount beneficially owned by each reporting person 7,968,056
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 7.3%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      FORTRESS BIOTECH, INC. (the “Issuer”).
       
    Item 1(b). Address of the Issuer’s Principal Executive Offices:
       
      1111 KANE CONCOURSE, BAY SUITE 301 HARBOR ISLANDS, FL 33154
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840 

       
    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, $0.001 par value (the “Shares”).

     

     

     

     

    CUSIP NO.  34960Q109 Page 5 of 7

     

    Item 2(e). CUSIP Number:
     

     

    34960Q109 

       
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: 
       
     

    (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).

       
    Item 4. Ownership:
       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2022, Nantahala may be deemed to be the beneficial owner of 7,968,056 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2022, each of the Reporting Persons may be deemed to be the beneficial owner of 7.3% of the total number of Shares outstanding.

     

     

     

     

    CUSIP NO.  34960Q109 Page 6 of 7

      

    Item 4(c). Number of shares as to which such person has:

             

     

    Nantahala Capital Management, LLC 

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 7,968,056
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 7,968,056

     

     

    Each of Messrs. Harkey and Mack  

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 7,968,056
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 7,968,056

      

    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:

      

     

    By signing below each Reporting Person certifies that, to the best of such person’s knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. 

     

     

     

     

    CUSIP NO.  34960Q109 Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2023 NANTAHALA CAPITAL MANAGEMENT, LLC 
         
      By: /s/ Taki Vasilakis
        Taki Vasilakis
        Chief Compliance Officer
         
      /s/ Wilmot B. Harkey 
      Wilmot B. Harkey 
         
      /s/ Daniel Mack 
      Daniel Mack 

     

     

     

    Get the next $FBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FBIO

    DatePrice TargetRatingAnalyst
    3/15/2024$10.00Buy
    ROTH MKM
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $FBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty rev

      5/15/25 4:05:12 PM ET
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

      UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corporate updates. Recent Corporate Updates: In December 2024, Checkpoint announced that the U.S. Food and Drug Administration ("FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the tr

      5/13/25 4:15:51 PM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Financials

    Live finance-specific insights

    See more
    • Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

      5/14/25 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

      UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corporate updates. Recent Corporate Updates: In December 2024, Checkpoint announced that the U.S. Food and Drug Administration ("FDA") approved UNLOXCYT™ (cosibelimab-ipdl) for the tr

      5/13/25 4:15:51 PM ET
      $CKPT
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Jin David was granted 5,000 shares, increasing direct ownership by 0.40% to 1,245,893 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      4/1/25 4:20:16 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lobell J Jay was granted 49,383 shares, increasing direct ownership by 43% to 165,075 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      1/3/25 4:28:30 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Klein Dov was granted 49,383 shares, increasing direct ownership by 92% to 102,783 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      1/3/25 4:20:17 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM resumed coverage on Fortress Biotech with a new price target

      ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00

      3/15/24 7:18:10 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Fortress Biotech with a new price target

      Ladenburg Thalmann initiated coverage of Fortress Biotech with a rating of Buy and set a new price target of $6.00

      8/4/22 7:17:35 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on Fortress Biotech with a new price target

      Roth Capital reiterated coverage of Fortress Biotech with a rating of Buy and set a new price target of $5.00 from $4.50 previously

      4/20/21 8:28:52 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fortress Biotech Inc.

      SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

      10/25/24 10:15:19 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

      SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

      9/25/24 4:45:18 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Fortress Biotech Inc. (Amendment)

      SC 13G/A - Fortress Biotech, Inc. (0001429260) (Subject)

      2/14/24 4:51:41 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

      SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

      7/11/24 4:05:39 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

      SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief

      5/1/24 4:01:30 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      9/25/24 4:45:04 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/15/24 4:05:14 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

      4 - Fortress Biotech, Inc. (0001429260) (Issuer)

      7/12/24 8:42:21 AM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Fortress Biotech Inc.

      10-Q - Fortress Biotech, Inc. (0001429260) (Filer)

      5/15/25 4:34:46 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Fortress Biotech, Inc. (0001429260) (Filer)

      5/15/25 4:10:12 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Fortress Biotech Inc.

      DEFA14A - Fortress Biotech, Inc. (0001429260) (Filer)

      4/28/25 4:15:14 PM ET
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care